GOLD COPD Report 2025: Key Spirometry and Drug Updates
Nov 22, 2024 · The 2025 GOLD COPD report has a new emphasis on CV disease and PH in COPD and major updates on new drugs, climate change, and more.
Updated 2023 GOLD Report Revises COPD Definitions and Treatment ...
The 2023 GOLD COPD report includes an updated exacerbation definition, new material on assessment and bronchitis, and new therapy recommendations.
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · The 2024 GOLD COPD Report includes updated research and recommendations that reflect shifts in thinking on COPD management.
Tezepelumab Gets Breakthrough Therapy Status for COPD Tx
Aug 12, 2024 · The FDA has granted Breakthrough Therapy designation to tezepelumab-ekko for use as an add-on maintenance treatment in patients with COPD.
GOLD COPD Update 2026: COPD Detection, Multimorbidity, AI
Nov 25, 2025 · Credit: Getty Images The 2026 GOLD COPD Update provides updated guidance on case-finding, disease activity, exacerbation management, and AI, as well as new criteria GOLD …
FDA Approves Nucala for COPD With an Eosinophilic Phenotype
Jun 3, 2025 · The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive …
Comparison of Single-Inhaler Triple Therapies in COPD
Jan 10, 2025 · The incidence of a first moderate or severe chronic obstructive pulmonary disease exacerbation was higher in patients who received budesonide-glycopyrrolate-formoterol compared …
In COPD Treatment, Tezepelumab Not Linked to Reduced Exacerbations
Jan 22, 2025 · Tezepelumab did not significantly decrease the annualized rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations compared with placebo, according to …
Ensifentrine Is a Promising Ancillary COPD Treatment Option
Jan 13, 2025 · A 3 mg dose of ensifentrine was linked to improved FEV1, dyspnea, and quality of life in patients with COPD, with few treatment-emergent adverse events. Ensifentrine is a promising …
Dupixent Approved as Add-On Maintenance Therapy in COPD
Oct 1, 2024 · The FDA has approved Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype.